Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 30:2021:9955456.
doi: 10.1155/2021/9955456. eCollection 2021.

2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology

Richard J Epstein  1   2 , Li Jun Tian  1 , Yan Fei Gu  1
Affiliations
Review

2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology

Richard J Epstein et al. J Oncol. .

Abstract

More than ten thousand peer-reviewed studies have assessed the role of fibroblast growth factors (FGFs) and their receptors (FGFRs) in cancer, but few patients have yet benefited from drugs targeting this molecular family. Strategizing how best to use FGFR-targeted drugs is complicated by multiple variables, including RNA splicing events that alter the affinity of ligands for FGFRs and hence change the outcomes of stromal-epithelial interactions. The effects of splicing are most relevant to FGFR2; expression of the FGFR2b splice isoform can restore apoptotic sensitivity to cancer cells, whereas switching to FGFR2c may drive tumor progression by triggering epithelial-mesenchymal transition. The differentiating and regulatory actions of wild-type FGFR2b contrast with the proliferative actions of FGFR1 and FGFR3, and may be converted to mitogenicity either by splice switching or by silencing of tumor suppressor genes such as CDH1 or PTEN. Exclusive use of small-molecule pan-FGFR inhibitors may thus cause nonselective blockade of FGFR2 isoforms with opposing actions, undermining the rationale of FGFR2 drug targeting. This splice-dependent ability of FGFR2 to switch between tumor-suppressing and -driving functions highlights an unmet oncologic need for isoform-specific drug targeting, e.g., by antibody inhibition of ligand-FGFR2c binding, as well as for more nuanced molecular pathology prediction of FGFR2 actions in different stromal-tumor contexts.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest relating to this work.

Similar articles

See all similar articles

Cited by

References

    1. Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends in Pharmacological Sciences. 2016;37(12):1081–1096. doi: 10.1016/j.tips.2016.10.003. - DOI - PubMed
    1. Coleman S. J., Bruce C., Chioni A.-M., Kocher H. M., Grose R. P. The ins and outs of fibroblast growth factor receptor signalling. Clinical Science. 2014;127(4):217–231. doi: 10.1042/cs20140100. - DOI - PubMed
    1. Rubin J. S., Bottaro D. P., Chedid M., et al. Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. Experientia Supplementum. 1995;74:191–214. doi: 10.1007/978-3-0348-9070-0_10. - DOI - PubMed
    1. Ornitz D. M., Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdisciplinary Reviews: Developmental Biology. 2015;4(3):215–266. doi: 10.1002/wdev.176. - DOI - PMC - PubMed
    1. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer. 2010;10(2):116–129. doi: 10.1038/nrc2780. - DOI - PubMed